Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program

Andreoni Massimo, Elisabetta Teti, Andrea Antinori, Laura Milazzoi, Savatore Sollima, Giuliano Rizzardini, Antonio Di Biagio, Annalisa Saracino, Raffaele Bruno, Vanni Borghi, Andrea De Luca, Annamaria Cattelan, Hamid Hasson, Gloria Taliani, Antonella D'Arminio Monforte, Claudio Maria Mastroianni, Giovanni Di Perri, Sara Bigoni, Massimo Puoti, Angiola SpinettiAndrea Gori, Nicola Boffa, Cacopardo Bruno, Andrea Giacometti, Giustino Parruti, Vincenzo Vullo, Antonio Chirianni, Alfredo Pennica, Caterina Pasquazzi, Daniela Segala, Loredana Sarmati, SIMIT (Società Italiana di Malattie Infettivee Tropicali)

Research output: Contribution to journalArticle

Abstract

Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).

Original languageEnglish
JournalClinical Infectious Diseases
DOIs
Publication statusE-pub ahead of print - Dec 22 2016

    Fingerprint

Keywords

  • Journal Article

Cite this

Massimo, A., Teti, E., Antinori, A., Milazzoi, L., Sollima, S., Rizzardini, G., Di Biagio, A., Saracino, A., Bruno, R., Borghi, V., Luca, A. D., Cattelan, A., Hasson, H., Taliani, G., Monforte, A. DA., Mastroianni, C. M., Di Perri, G., Bigoni, S., Puoti, M., ... SIMIT (Società Italiana di Malattie Infettivee Tropicali) (2016). Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciw846